ALX Oncology Reports Data From ASPEN-06 Phase 2 Trial; Says Evorpacept Combination Achieved Confirmed Overall Response Rate Of 40.3% Compared To 26.6% For Control Arm
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology reported positive data from its ASPEN-06 Phase 2 trial, showing that the evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm. In patients with fresh HER2-positive biopsies, the ORR was 54.8% versus 23.1% in the control, indicating a strong correlation between HER2 expression and evorpacept efficacy.
July 31, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ALX Oncology's ASPEN-06 Phase 2 trial results show a significant improvement in ORR for evorpacept combination therapy, particularly in HER2-positive patients. This could lead to increased investor confidence and a potential rise in stock price.
The positive trial results, especially the high ORR in HER2-positive patients, validate evorpacept's mechanism of action and its potential as a treatment. This is likely to boost investor confidence and positively impact ALXO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100